Literature DB >> 11893808

Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium.

Inmaculada A Herrero, Nicolas C Issa, Robin Patel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11893808     DOI： 10.1056/NEJM200203143461121

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  48 in total

1.  Enterococcal endocarditis: can we win the war?

Authors:  Jose M Munita; Cesar A Arias; Barbara E Murray
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

2.  In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.

Authors:  Ji-Woong Jeong; Sung-Ji Jung; Hyun-Hee Lee; Yong-Zu Kim; Tae-Kyo Park; Young-Lag Cho; Sang-Eun Chae; Sung-Yoon Baek; Sung-Ho Woo; Hyang-Sook Lee; Jin-Hwan Kwak
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

Review 3.  Strategies to combat chronic critical illness.

Authors:  Jennifer M Maguire; Shannon S Carson
Journal:  Curr Opin Crit Care       Date:  2013-10       Impact factor: 3.687

4.  In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals.

Authors:  Maria Souli; Flora V Kontopidou; Evangelos Koratzanis; Anastasia Antoniadou; Efthimia Giannitsioti; Pinelopi Evangelopoulou; Sofia Kannavaki; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

5.  Molecular detection of linezolid resistance in Enterococcus faecium and Enterococcus faecalis by use of 5' nuclease real-time PCR compared to a modified classical approach.

Authors:  Guido Werner; Birgit Strommenger; Ingo Klare; Wolfgang Witte
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

6.  In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria.

Authors:  Eun Jeong Yoon; Yeong Woo Jo; Sung Hak Choi; Tae Ho Lee; Jae Keol Rhee; Moohi Yoo; Mi Ja Shim; Eung Chil Choi
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

7.  Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States.

Authors:  Rodrigo E Mendes; Robert K Flamm; Patricia A Hogan; James E Ross; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

8.  Tedizolid susceptibility in linezolid- and vancomycin-resistant Enterococcus faecium isolates.

Authors:  E-M Klupp; A Both; C Belmar Campos; H Büttner; C König; M Christopeit; M Christner; M Aepfelbacher; H Rohde
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-15       Impact factor: 3.267

9.  Pharmacokinetics of linezolid in septic patients with and without extended dialysis.

Authors:  Stefanie Swoboda; Michael C Ober; Christoph Lichtenstern; Soundos Saleh; Vedat Schwenger; Hans-Günther Sonntag; Walter Emil Haefeli; Georg Hempel; Torsten Hoppe-Tichy; Markus A Weigand
Journal:  Eur J Clin Pharmacol       Date:  2009-12-16       Impact factor: 2.953

Review 10.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.